Thus, differences in gene expression patterns together with the hormone receptor status of the cells may contribute to their differential responses to polyamine pathway inhibition and may help predict the sensitivity of breast cancers to polyamine targeting therapy. This evidence concerns the gene NR4A1 and breast carcinoma.